ArticleThe Lancet regional health. Europe2026
Comparing outcomes of COVID-19 and influenza among hospitalized adults in the European severe acute respiratory infection vaccine effectiveness (EuroSAVE) network, 2021-2024: a retrospective cohort analysis.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding changes in the severity of respiratory virus infections over time is critical for guiding public health interventions. Few studies have been conducted in middle-income countries (MICs), where healthcare infrastructure, COVID-19 and influenza vaccine coverage, and antiviral availability and use differ from high-income countries. Methods: We compared the odds of severe outcome and death by virus test result among patients ≥18 years old hospitalized with severe acute respiratory infection (SARI) in five MICs and areas (Albania, Georgia, Kyrgyzstan, North Macedonia, and Kosovo). Severe outcome included ICU admission, mechanical ventilation, ECMO, or death during hospitalization. We calculated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for severe outcome and death by respiratory virus PCR test result. Influenza-positive patients were the reference group. We grouped SARS-CoV-2 patients into three periods based on COVID-19 activity and circulating Omicron subvariants [Period 1 (6 December 2021-18 December 2022), Period 2 (19 December 2022-9 July 2023), and Period 3 (10 July 2023-6 August 2024).] We adjusted for age, sex, comorbidities, COVID-19 vaccination status, and country. Findings: Of 7671 patients who met the inclusion criteria, 963 (13%) patients had a severe outcome; 749 (10%) were admitted to ICU, 202 (3%) received mechanical ventilation or ECMO and 285 (4%) died. Compared to influenza patients, SARS-CoV-2-positive patients had a higher odds of severe outcome in Period 1 [ aOR = 1.80 (95% CI 1.23-2.64)], P2 [aOR = 1.94 (95% CI 1.25-3.01)], and Period 3 [aOR = 1.63 (95% CI 1.05-2.54)]. COVID-19 patients in Period 1 (aOR = 2.80; 1.67-4.82) and Period 3 (aOR = 2.25; 95% CI 1.23-4.18) had a higher aOR for death compared to influenza-positive patients; for Period 2 the aOR was 1.04 (95% CI 0.48-2.15). Interpretation: The odds of severe outcome were higher for SARS-CoV-2 patients compared to influenza-positive patients for all periods, while the odds of death were higher during Period 1 and Period 3. These results underscore the continued severity of COVID-19, and need for COVID-19-related health interventions, including COVID-19 vaccination and in-hospital patient management. Funding: This study was funded by the World Health Organization/Regional Office for Europe, in part through a cooperative agreement with the U.S. Centers for Disease Control and Prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.